Ketoconazole and candidiasis: a controlled study.

Abstract

A double-blind, placebo-controlled study was undertaken to determine the efficacy of ketoconazole in the treatment of candidiasis. The drug was administered orally in the dosage of 200 mg/m2 of body surface per day for two weeks to cancer patients with oral candidiasis. Randomization in a 2:1 ratio provided 36 patients treated with ketoconazole and 20 managed with a placebo. Regression of visible lesions was achieved in 26 (72%) of 36 ketoconazole-treated and four (20%) of 20 untreated patients; eradication of culturable organisms occurred in 12 (36%) of 33 ketoconazole-treated and one (7%) of 14 untreated patients; and resolution of lesions plus eradication of Candida albicans occurred in nine (25%) of 36 ketoconazole-treated and one (5%) of 20 untreated patients. Although the therapeutic efficacy of ketoconazole was demonstrated for oropharyngeal candidiasis, the magnitude of its efficacy was less than that desired.

• Authors: W T Hughes, D L Bartley, G G Patterson, H Tufenkeji
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 147 Issue 6 Pg. 1060-3 (Jun 1983) ISSN: 0022-1899 [Print] United States
• PMID: 6304203 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Antifungal Agents
• Imidazoles
• Piperazines
• Ketoconazole

Topics

• Adolescent
• Antifungal Agents (therapeutic use)
• Candidiasis, Oral (complications, drug therapy)
• Child
• Clinical Trials as Topic
• Double-Blind Method
• Humans
• Imidazoles (adverse effects, therapeutic use)
• Ketoconazole
• Neoplasms (complications)
• Piperazines (adverse effects, therapeutic use)
• Random Allocation